{
    "nctId": "NCT00754325",
    "briefTitle": "Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor",
    "officialTitle": "Phase II Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor",
    "overallStatus": "COMPLETED",
    "conditions": "Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Number of Participants With Disease Progression (PD) or Death",
    "eligibilityCriteria": "For more information regarding Bristol-Myers Squibb (BMS) clinical trial participation, please visit www.BMSStudyConnect.com.\n\nInclusion Criteria:\n\n* Histologically confirmed hormone receptor positive (HR+) \\[(estrogen receptor (ER+) and/or progesterone receptors(PgR+)\\] breast cancer according to immunohistochemistry (IHC)\n* Measureable or evaluable-only disease\n* human epidermal growth factor receptor 2+ (HER2+) or HER2- breast cancer\n* Males and females \u226518 years of age\n* Females are post menopausal or surgically sterile\n* Recurrent or progressive advanced breast cancer (locally-advanced or metastatic), that has progressed: (a) during or within 12 months after completion of adjuvant Aromatase Inhibitor (AI) treatment OR (b) during AI treatment in advanced setting (metastatic therapy)\n\nExclusion Criteria:\n\n* Pregnant or breast feeding\n* \\>1 chemotherapy regimen for advanced disease\n* Pleural or pericardial effusion\n* Serious cardiac condition",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}